Patent Application
20200173991
The present invention relates to an antibody which specifically reacts with an N-terminus neo-epitope of collagen type X alpha 1, and its use in a method of immunoassay for detecting and quantifying collagen type X alpha 1.
Osteoarthritis (OA) is a common joint disease which is characterized by cartilage damage and loss of joint function. The etiology of OA comprises multiple factors including aging, obesity, trauma and heredity [1]. The pathogenesis of OA is poorly understood due to the heterogeneity and complexity of this disease.
Remarkably, some characteristics of OA resemble chondrocyte differentiation processes during skeletal development by endochondral ossification. In healthy articular cartilage, chondrocytes resist proliferation and terminal differentiation. By contrast, chondrocytes in diseased cartilage progressively proliferate and develop hypertrophy. Moreover, vascularization and focal calcification of joint cartilage are initiated [2-5]. The molecular events regulating chondrocyte differentiation are still unknown, but chondrocyte hypertrophy-like changes in OA have attracted more attention for study [6-8].
Collagen type X alpha-1 is non-fibrillar, but forms fine pericellular filaments in association with cartilage collagen. The molecule isolated from chondrocyte cultures or from cartilage is a homotrimer of 59 kDa Collagen type X alpha-1 chains, and there have been reports of a recombinant molecule of collagen type X of approximately 75 kDa [9]. Collagen type X alpha-1 shares a similar domain structure with type VIII collagen: a central triple-helical (COL1) domain of 50 kDa is flanked by N-terminal (NC2) and C-terminal (NC1) non-triple-helical domains [10]. In addition, both collagen types represent major components of hexagonal lattice structure, in which the collagen molecules link together by interactions involving the non-triple-helical end regions.
Collagen type X alpha-1 distribution is restricted to normal fetal hypertrophic cartilage in the growth zones of long bones, vertebrae and ribs, and in adult (>21 yr) thyroid cartilage, where it may provide a scaffold to prevent local collapse as the cartilage matrix is removed during endochondral ossification [11]. It is also found in bone fracture callus, in osteoarthritic cartilage and in chondrogenic neoplasms, and may be involved in cartilage mineralization.
OA is generally considered to be a non-inflammatory condition of the synovial joints, predominantly knee and hips. Chondrocyte hypertrophy and cartilage calcification are key pathological events in OA. Elevated expression of network-forming type X collagen is believed to be a specific signal for chondrocyte hypertrophy [12-15] therefore type X collagen can be used as a detectable marker for said disease.
There are several proteins associated with hypertrophic chondrocytes, such as collagen type X, MMP13, osteopontin, osteocalcin [16], Indian Hedgehog [17], Runx2 [18], VEGF [19], HtrA1 [20] and Transglutaminase-2 (TG-2) [21]. Collagen type X and MMP13 are among the most widely used as markers of hypertrophic chondrocytes. However, synthesis of MMP13 can be induced in chondrocytes by inflammation and mechanical stress [22-23]. Therefore, collagen type X as a hypertrophic chondrocyte specific marker can indicate a phenotype alteration of chondrocytes.
Thus, a method which accurately quantifies the amount of collagen type X or its fragments in a biological sample may allow a better understanding of collagen type X pathologies or physiological processes affecting collagen type X turnover such as OA. Evidently there is a need for such a method.
The inventors have now found that cathepsin K cleaves collagen type X alpha 1 at the peptide link between 478A-G479, resulting in the formation of the N-terminus neo-epitope biomarker H2N-479GIATKGLNGP (SEQ ID NO: 1). This neo-epitope biomarker of collagen type X alpha 1 has been shown to correlate well with osteoarthritis.
Thus, in a first aspect the present invention relates to an antibody, wherein said antibody specifically binds to an N-terminus neo-epitope of collagen type X alpha 1 comprised in the amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1).
Preferably, the antibody specifically binds to the N-terminus amino acid sequence H2N-GIATKG (SEQ ID NO: 2).
Preferably, the antibody does not specifically recognise or bind an N-extended elongated version of said N-terminus amino acid sequence. In this regard “N-extended elongated version of said N-terminus amino acid sequence” means one or more amino acids extending beyond the N-terminus of the sequence H2N-GIATKGLNGP (SEQ ID NO: 1). For example, if the N-terminal amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) was elongated by an alanine residue then the corresponding “N-extended elongated version” would be H2N-AGIATKGLNGP . . . (SEQ ID NO: 3). Similarly, it is preferable that the antibody does not specifically recognise or bind an N-truncated shortened version of said N-terminus amino acid sequence. In this regard “N-truncated shortened version of said N-terminus amino acid sequence” means one or more amino acids removed from the N-terminus of the sequence H2N-GIATKGLNGP (SEQ ID NO: 1). For example, if the N-terminal amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) was shortened by one amino acid residue then the corresponding “N-truncated shortened version” would be H2N-IATKGLNGP . . . (SEQ ID NO: 4).
The antibody is preferably a monoclonal antibody or fragment thereof. The invention includes a cell line producing such a monoclonal antibody or fragment thereof.
In a second aspect the present invention relates to a method of immunoassay for detecting in a biological sample fragments of collagen type X alpha 1 comprising an N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1), said method comprising contacting said biological sample comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) with an antibody as described above, and determining the amount of binding of said antibody.
Preferably, said method is quantitative.
Preferably, said method is used to detect and/or quantify the amount of fragments of collagen type X alpha 1 comprising the N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) in biofluid.
The biofluid may be a patient derived biofluid. The biofluid may be, but is not limited to, blood, urine, synovial fluid, serum, plasma, or amniotic fluid.
The method of immunoassay may be, but is not limited to, a competition assay or a sandwich assay. The method of immunoassay may be, but is not limited to, a radioimmunoassay or an enzyme-linked immunosorbent assay.
The method may further comprise correlating the quantity of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) determined by said method with standard disease samples of known disease severity to evaluate the severity of a disease associated with collagen type X alpha 1.
Alternatively, or in addition to, the method may further comprise comparing the quantity of said fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) determined by said method with standard values associated with healthy subjects to evaluate the presence and/or severity of a disease associated with collagen type X alpha 1.
In that regard, said method may further comprise correlating the quantity of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) determined by said method with standard osteoarthritis samples of known severity.
Similarly, said method may further comprise correlating the quantity of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) determined by said method with standard osteoarthritis samples of known severity in subjects of known age and gender and/or standard values associated with healthy subjects to evaluate the presence and/or severity of osteoarthritis. In this regard the comparison of samples is preferably between patient derived samples, wherein the patients (from whom the samples are derived) are of the same gender and of similar age to the standard samples.
The method may further comprise quantifying the amount of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) in at least two samples obtained from a subject at a first time point and at least one subsequent time point, wherein a change in the quantity of said fragments from the first time point to the at least one subsequent time point is indicative of a change in the status of a disease associated with collagen type X alpha 1 from the first time point to the at least one subsequent time point.
For example, when the disease associated with collagen type X alpha 1 is osteoarthritis, an increase in the quantity of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) from the first time point to the at least one subsequent time point is indicative of a deterioration in osteoarthritis in a subject from the first time point to the at least one subsequent time point. Similarly, a decrease in the quantity of fragments of collagen type X alpha 1 comprising said N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) from the first time point to the at least one subsequent time point is indicative of an improvement in osteoarthritis in a subject from the first time point to the at least one subsequent time point.
In a final aspect, the present invention relates to an assay kit for detecting fragments of collagen type X alpha 1 comprising the N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1) in a biological sample, said kit comprising an antibody as described above and at least one of:
As used herein the term “N-terminus” refers to the extremity of a polypeptide, i.e. at the N-terminal end of the polypeptide, and is not to be construed as meaning in the general direction thereof.
As used herein the term “N-terminus neo-epitope” refers to an N-terminus epitope formed by cleavage of a protein by a protease. For the instant invention this means an N-terminus epitope formed by cleavage of Collagen type X alpha-1 by cathepsin K.
As used herein the term “fragments of collagen type X alpha 1 comprising an N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1)” means peptide fragments of collagen type X alpha 1 wherein the N-terminus of the peptide fragment is the amino acid sequence H2N-GIATKGLNGP . . . (SEQ ID NO: 1).
As used herein the term, the term “competitive ELISA” refers to a competitive enzyme-linked immunosorbent assay and is a technique known to the person skilled in the art.
As used herein the term “sandwich immunoassay” refers to the use of at least two antibodies for the detection of an antigen in a sample, and is a technique known to the person skilled in the art.
As used herein, the term “Col10neo” is used as shorthand to describe the herein disclosed specific assay for detecting and quantifying fragments of collagen type X alpha-1 comprising the N-terminus neo-epitope amino acid sequence H2N-GIATKGLNGP (SEQ ID NO: 1).
The presently disclosed embodiments is described in the following Examples, which are set forth to aid in the understanding of the disclosure, and should not be construed to limit in any way the scope of the disclosure as defined in the claims which follow thereafter. The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the described embodiments, and are not intended to limit the scope of the present disclosure nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
In the following examples, the following materials and methods were employed.
Unless otherwise stated, all materials used for experiments were of high quality and ordered from Sigma-Aldrich (Copenhagen, Denmark) or VWR (Rodedovre, Denmark). The synthetic peptides used for monoclonal antibody production and assay development were purchased from GenScript (USA). MMP-2 catalytic domain (cat # GO4MP02C), MMP-9 catalytic domain (cat # GO4MP09C) and MMP-13 catalytic domain (cat # G04MP13C) were bought from Gitto Biotech (Florence, Italy). Cathepsin K (cat #219461), Cathepsin B (cat #219362) and Cathepsin S (cat #219343) and ADAMTS-4 (cat # CC1028) were from Merck Millipore (Darmstadt, Germany). ADAMTS-5 (cat #2198-AD-20) was purchased from R&D system (Minnesota, USA).
The analysis for naturally occurring peptides in human urine from OA patients was carried out by LC-MS/MS. A significant amount of peptide fragments were identified in human OA urine. 17 peptide sequences were found to be unique to human type X collagen. Two among 17 sequences carrying the same free c-terminus located at amino acid (aa) position 478′ (Accession No.: Q03692; Database: UniProt) were present in the diseased urine, indicating the cleavage occurring between the bond of A478-479G. The first 10 aa, 479GIATKGLNGP488 (SEQ ID NO: 1), of the free N-terminal end generated by this cleavage was selected for immunization. The sequence alignment from different species was also analyzed using the Basic Local Alignment Search Tool (BLAST, see Table 1).
Monoclonal Antibody (mAb) Production
Six female Balb/C mice of 6-7 weeks of age were immunized subcutaneously with emulsified GIATKGLNGP-GGC-KLH (SEQ ID NO: 6) with Sigma Adjuvant System®(cat # S6322, Sigma-Aldrich). 100 μg of emulsified KLH-conjugate with adjuvant was repeatedly injected into mouse every 3rd week until stable titer levels were obtained. At each bleeding, the serum antibody titer was measured against the biotinylated peptide, GIATKGLNGP-k(Biotin) (SEQ ID NO: 5) coated on streptavidin coated microplates (Roche Diagnostics, Germany). The mice with the highest antibody titer and best reactivity towards the selection peptide, GIATKGLNGP (SEQ ID NO: 1), was chosen for fusion (data not shown). The mouse selected was boosted intraperitoneally (i.p.) with 100 μg KLH-conjugate in 100 μL 0.9% sodium chloride solution three days before sacrificed for fusion. The fusion and antibody screening process was performed using standard techniques. Briefly, the spleen was surgically removed for isolation of splenocytes which was fused with murine myeloma cells, SP2/0-Ag14 (ATCC®CRL-1581™) Hybridoma cells were selected by using HAT (hypoxanthine Aminopterin Thymidine) medium. Supernatants were screened by an indirect ELISA, where the biotinylated peptide, GIATKGLNGP-k(Biotin) (SEQ ID NO: 5) was coated on streptavidin-precoated microplates. Standard limiting dilution process was carried out to select single cells. The isotype of antibody in supernatant was tested using the isotype determination kit, SBA Clonotyping System-HRP (5300-05, Southern Biotech). Single-cell derived hybridoma were transferred to 24-well plate to allow them for further growth, and eventually scale up from T25 to T175 flasks. The supernatants were collected and filtered with 0.2 μm filter before applying to a 1 mL HiTrap Protein G HP column (cat #17-0404-01, GE healthcare) for antibody purification.
A purified monoclonal antibody was first tested for peptide-binding specificity by three synthetic peptides, selection peptide (GIATKGLNGP; SEQ ID NO: 1), elongation of the selection peptide (AGIATKGLNGP; SEQ ID NO: 3) and truncation of the selection peptide (IATKGLNGP; SEQ ID NO: 4), and then used in a competitive immunoassay. After optimization with buffer, temperature, incubation time and concentrations for key reagents, the final protocol for detection of 479GIATKG (SEQ ID NO: 2) assay was developed as follows: a 96-well streptavidin pre-coated micro plate was coated with 1 ng/ml biotinylated peptide, GIATKGLNGP-k(Biotin) (SEQ ID NO: 5) dissolved in 50 mM PBS-BTB buffer (phosphate-buffered saline with bovine serum albumin and Tween-20, pH7.4) for 30 min at 20° C. Then, the plate was washed 5 times by standard wash buffer (20 mM Tris, 50 mM NaCl, pH 7.2). 20 μL of the peptide standards, kit controls or samples were added to appropriate wells, followed by 100 μL of 23 ng/ml monoclonal antibody in 50 mM PBS-BTB buffer containing 5% Osteocalcin EIA Puf-Liq (Roche diagnostics, Germany), and incubated overnight (20±1 hr) at 4° C. After 5 times wash, 100 μL of goat anti-mouse secondary antibody (115-035-003, Jackson ImmunoResearch) was added and incubated for 1 hr at 20° C. After this step, the plate was washed for 5 times with wash buffer. Finally, 100 μL 3,3′,5,5′-tetramethylbenzidine (TMB) was added to each well and incubated for 15 min at 20° C. in the dark. The colorimetric reaction was stopped by adding 100 μL stopping solution (1% H2SO4) and measured at 450 nm with 650 nm as the reference.
The inter- and intra-plate variation were determined by 10 independent runs of quality control panel (three human sera and two peptide standard) in duplicate. The lower limit of detection (LLOD) was calculated as 3SD of the mean value of 21 zero standard. Multiple human serum or plasma samples were assayed neat, 2, 4, 6, 8, 16-fold in incubation buffer. Percent recovery was calculated as the measured concentration divided by the expected concentration corrected for dilution.
Articular cartilage biopsies from osteoarthritis (OA) patients who underwent knee replacement surgery were obtained from Gentofte Hospital (Gentofte, Denmark). The retrieval of the specimens complied with international ethical guidelines for handling human samples and patient information. All participants signed an informed consent and the study was approved by Danish authority. To identify the enzymes responsible for the cleavage of the A478-479G bond, cartilage was cleaved by numerous proteases including matrix metalloproteases (MMP2, MMP9 and MMP13), Cathepsins (CatK, CatB and CatS), and A disintegrin and metalloprotease domains with thrombospondins motifs (ADAMTS-4 and ADAMTS-5). 30 mg of snap-frozen and crushed cartilage with 1 μg each enzyme were placed in a 0.5 ml Eppendorf with 250 μL digestion buffer (digestion buffer for MMPs: 100 mM Tris, 100 mM NaCl, 10 mM CaCl2 and 2 mM zinc acetate, pH 8.0; digestion buffer for ADAMTSs: 50 mM Tris, 100 mM NaCl and 10 mM CaCL2, pH 7.5; digestion buffer for Cathepsins: 25 mM NA2HPO4, 150 mM NaCl, 2 mM EDTA, 2 mM DTT, pH 6.5). The digestion was carried out on one day in 2 replicates. 5 mM EDTA (broad-spectrum inhibitor for MMPs and ADAMTSs) and 5 mM E64 (broad-spectrum inhibitor for Cathepsins) were added to stop the reaction. All supernatants were stored at −80° C. prior to use.
Cartilage with bone specimens for IHC were from the study in collaboration with Frederikshavn Hospital (Denmark) approved by Danish authority (N-20110031). All participants signed an informed consent. The specimens isolated from OA patients who underwent knee replacement surgery were fixed and decalcified, and then embedded in paraffin. 5 μm-thick cartilage sections were melt at 60° C. for 1 hr and deparrifined and hydrated, followed by antigen retrieval using Pronase E (cat #10165921001, Roche) at 37° C. for 10 min. The sections were treated by 0.5% casein in Tris Buffered Saline (TBS) for 30 min at room temperature to block unspecific binding. Immunostaining was performed by antibody NB117-2F4 developed in this study and previously developed antibody NB509-11G8. Immunoreactivity was visualized with peroxidase labeled anti-Mouse and diaminobenzidine (DAB, Dako, Denmark). Counterstaining was with Mayer's hematoxylin. The pictures were taken using an Olympus microscope BX60 equipped with an Olympus C5050 digital camera.
Plasma samples were retrieved from two studies, the C4Pain study approved by local ethics committee (N-20100094) [24] and the NYUHJD Progression study approved by local ethics committee [25, 26]. All participants provided informed consent prior to enrollment.
Briefly, the C4Pain is a cross-sectional study. It comprised 281 individuals with no joint degeneration to severe joint degeneration using the Kellgren/Lawrance (K/L) grading scale (K/L 0-4). The plasma samples from 253 enrollees were measured in the present study due to insufficient volume of other 28 samples.
The NYUHJD Progression study comprised 21 non-OA healthy controls (K/L≤1 and no pain in either knee), 146 OA patients (K/L≥2) and 36 rheumatoid arthritis (RA) patients at baseline. 146 OA patients were further followed up for 24 months. The radiographic assessments were taken at baseline and 24 months and plasma were collected at baseline. Plasma samples from 20 non-OA healthy controls, 142 OA subjects and 34 RA subjects at baseline were available for measurement in the present study. However in the present study, we only investigated the level of Col10neo in different groups at baseline. Future studies will continue to move toward a more complete picture of Col10neo as a potential prognostic biomarker of radiographic progression in OA.
Data were analyzed using GraphPad Prism 6 or MedCalc 16.8. For normality check, a Shaprio-Wilk test for all variables of interest was performed. Between group comparison for age, BMI and VAS score, the one-way ANOVA with post-hoc Tukey-Kramer test was used. Plasma Col10neo data were logarithmic transformed in all analyses. P value<0.05 was considered statistically significant. One asterisk (*) if p<0.05; two (**) if p<0.01; three (***) if p<0.001 and four (****) if p<0.0001.
Sequence alignment of the selected peptide across species 2 fragments sharing the same free C-terminal end, 463PGSKGDPGSPGPPGPA478 (SEQ ID NO: 7) and 465SKGDPGSPGPPGPA478 (SEQ ID NO: 8) were identified by mass spectrometry in urine of OA patients, indicating the presence of a cleavage site existing between A478-479G. A 10aa peptide from the free N-terminus generated by the cleavage, 479GIATKGLNGP (SEQ ID NO: 1), was chosen for immunization. The blast shows that among human proteins the sequence is unique to type X collagen alpha-1. Sequence similarity across species shows 100% identity between human and mouse, while a mismatched aa is contained in rat or bovine compared to human sequence.
Homo sapiens
1
Rattus
norvegicus
2
Mus Musculus
3
Bos taurus
4
Canis lupus
familiaris
5
1Human (SEQ ID NO: 1); 2Rat (SEQ ID NO: 9); 3Mouse (SEQ ID NO: 10); 4Bovine (SEQ ID NO: 11); 5Dog (SEQ ID NO: 12)
The monoclonal antibody 2F4 (isotype: IgG2b, K) targeting 479GIATKG (SEQ ID NO: 2) was produced from hybridoma and purified by HiTrap Protein G affinity column (Cat #17-0404-01, GE Healthcare). In test for peptide-binding specificity, the reactivity of 2F4 toward a biotinylated synthetic peptide, GIATKGLNGP-k(Biotin) (SEQ ID NO: 5), was completely displaced by adding of 1000 ng/mL selection peptide. In contrast, a slight or no displacement was observed with elongation of the selection peptide or truncation of the selection peptide at the same concentration (
The antibody 2F4 showing great specificity was therefore applied in a competitive ELISA assay, Col10neo. The technical performance of this assay is summarized and listed in table 2. The IC50 was 41.9 ng/mL. The intra-assay coefficient variation (CV %) was 3% and the inter-assay CV % was 11.8. The measurement range was 8-250 ng/mL. The linearity was good over a wide range of 4- to 32-fold dilution of serum and 8- to 64-fold dilution of EDTA-anticoagulated plasma.
To investigate the responsible enzyme for cleaving A478-479G bond, several proteases were individually incubated with human cartilage. All proteases were at the same enzyme concentration and all incubations were performed for the same incubation time. The relative efficiency for each protease to generate the neo-epitope of 479GIATKGLNGP (SEQ ID NO: 1) was evaluated by applying to the Col10neo assay. There was no increased level of Col10neo in any of the tested MMPs or ADAMTSs solution compared to the one without adding proteases in the digestion buffer (
To further define the generation and distribution of 479GIATKG (SEQ ID NO: 2), consecutive sections of articular cartilage from a TKR (total knee replacement) patient were stained with anti-479GIATKG (SEQ ID NO: 2) (2F4), normal mouse IgG (negative control) and anti-C terminus of type X collagen (11G8-disclosed in WO 2014/180992) as well. We did not observe any staining with normal mouse IgG (
The 253 participants from the C4Pain study were categorized into 4 groups based on the K/L grade. The demographic characteristics of these 4 groups are summarized in table 3.
67.8 ± 7.7$
Except where indicated otherwise, values are the mean±SD.
Vas grade=maximal pain intensity for the last
24 hour, BMI=body mass index.
$, P<0.05 compare to K/L0-1 group
As the mean age of the participants was >60 years, the few participants with a K/L 0 or K/L of 1 were classified into the same group. 57% of the subjects involved in this study were with a K/L of 2 and assigned to group 2. There was no significant difference in gender distribution within each group. The mean age of K/L4 was significantly higher than K/L 0-1 group (p<0.005). There was a clear but not significant trend of increased BMI with an increase in K/L grade. The mean value of VAS score, defined as the maximal pain intensity for the last 24 hours, was not significantly different from each group.
The mean±95CI % concentrations of Col10neo for participants in 4 groups from KL 0-4 were 2.6 [2.316-2.884] μg/mL, 3.288[2.885-3.691] μg/mL, 3.435[2.729-4.141] μg/mL and 3.517[2.599-4.435] μg/mL, respectively. There was a trend toward increased Col10neo levels with a greater K/L grade, but that did not reach statistical significance (
The result from the C4Pain study caused us to investigate the potential of using Col10neo as a diagnostic biomarker in the NYUHJD Progression study which consists of non-OA healthy control, OA and RA. The percentage of female participants was higher in OA and RA groups than in the healthy control group. The mean age was significantly different in control and OA groups. However, the subjects were significantly younger in the RA group than in the OA group, since RA can occur at any age but has its peak between ages 30-55. There was a slight difference in BMI between healthy control and OA.
The plasma Col10neo (mean±95CI %) in control, OA and RA was 2.953[2.711-3.194]μg/mL, 4.04[3.835-4.246]μg/mL and 2.548[2.285-2.81]μg/mL, respectively (
Surprisingly, when adjusted for age and gender the difference between the control and Col10neo became significant for RA (p=0.0084; Table 5).
a Bonferroni corrected
It has been demonstrated that the herein disclosed col10neo assay is useful in the evaluation of OA.
It is herein proposed that this usefulness may extend to evaluating other diseases associated with collagen type X alpha-1, such as ankylosing spondylitis.
In this specification, unless expressly otherwise indicated, the word ‘or’ is used in the sense of an operator that returns a true value when either or both of the stated conditions is met, as opposed to the operator ‘exclusive or’ which requires that only one of the conditions is met. The word ‘comprising’ is used in the sense of ‘including’ rather than in to mean ‘consisting of’. All prior teachings acknowledged above are hereby incorporated by reference. No acknowledgement of any prior published document herein should be taken to be an admission or representation that the teaching thereof was common general knowledge in Australia or elsewhere at the date hereof.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1712071.8 | Jul 2017 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2018/070430 | 7/27/2018 | WO | 00 |
